Unicefy AstraZeneca signed a long-term agreement this week for the provision of the COVID-19 vaccine on behalf of the Covax Facility, launched by the Coalition for the Promotion of Innovations for Epidemic Preparedness (CEPI), the Gavi Alliance for Vaccines (Gavi) and the World Health Organization (WHO) to achieve equitable access to the vaccine globally. Under this agreement, Unicef and other procurement partners, including the Pan American Health Organization (PAHO), will have access to up to 170 million doses of vaccines for around 85 countries. This is the third such agreement for Covid-19 vaccines, following those already announced with Pfizer and the Serum Institute of India.Deliveries of the vaccine are expected to begin in the first quarter of 2021, in accordance with the Covax Allocation Framework, which takes into account several factors, including: country readiness, national regulatory authorizations and contractual provisions finalized , as well as other operational and supply considerations. This supply agreement will allow access to 170 million doses guaranteed under the Early Acquisition Agreement (APA, The Covax Mechanism with AstraZeneca, which will be available throughout 2021.On 11 February Unicef announced the signing of an agreement with Pfizer for the supply of its vaccine during 2021, as a result of an agreement with the Serum Institute of India to access two vaccines by transferring AstraZeneca technology , included in WHO’s Emergency Use Products List (EUL) on 15 February, and Novavax, subject to WHO approval of the vaccine. The Covax Mechanism aims to provide at least 2 billion doses of Covid-19 vaccines approved by the end of 2021, protecting frontline health workers and social workers, as well as other vulnerable and high-risk groups. Its goal is to ensure that safe and effective Covid-19 vaccines are available quickly and affordable to all countries around the world, regardless of income level.